DAPHNe: De-escalation to adjuvant antibodies post-pCR to Neoadjuvant THP (paclitaxel/trastuzumab/pertuzumab) - a pilot study in HER-2 positive breast cancer (DF/HCC 18-394)

Study Details

This research study is studying whether participants and their doctors are willing to determine post-surgery treatment on the basis of response to pre-surgery treatment, and studying blood and tissue collected from participants treated with a combination of drugs as a treatment for breast cancer.

The names study drugs involved in this study are:

  • Paclitaxel (also called Taxol)
  • Trastuzumab (also called Herceptin)
  • Pertuzumab (also called Perjeta)

Learn More

ClinicalTrials.gov NCT number
NCT03716180

Principal Investigators

  • Steve Lo, MD
Contact
Mary Miller, LPN at 203-358-8879
or officeofresearch@stamhealth.org

Location

  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695
There is no panel matching the key "Cookie-Notification"